Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 4/20 | 0.73 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.73 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.73 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.73 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.73 |
| ▸ | SCN1A | P35498 | 2/20 | 0.73 |
| ▸ | HTR2B | P41595 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.73 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.73 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.73 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612520 | 1.00 | CACNA1C (0.73) | CACNA1CCACNA1DADORA3CACNA1BCACNA1F | |
| SCHEMBL9138577 | 0.95 | CACNA1C (0.67) | CACNA1CCACNA1DADORA3CACNA1BCACNA1F | |
| SCHEMBL7265431 | 0.92 | ADORA3 (0.63) | CACNA1CCACNA1DADORA3CACNA1BCACNA1F | |
| SCHEMBL7272518 | 0.92 | CACNA1D (0.63) | CACNA1CCACNA1DADORA3CACNA1BCACNA1F | |
| SCHEMBL7272521 | 0.92 | CACNA1D (0.63) | CACNA1CCACNA1DADORA3CACNA1BCACNA1F | |
| Nifedipine SCHEMBL4440304 | 0.91 | ADORA3 (0.90) | CACNA1CCACNA1DADORA3CACNA1BCACNA1F | |
| SCHEMBL719056 | 0.91 | ADORA3 (0.90) | CACNA1CCACNA1DADORA3CACNA1BCACNA1F | |
| SCHEMBL7266381 | 0.89 | CACNA1B (0.74) | CACNA1CCACNA1DADORA3CACNA1BCACNA1F | |
| SCHEMBL7412221 | 0.89 | CACNA1B (0.74) | CACNA1CCACNA1DADORA3CACNA1BCACNA1F | |
| SCHEMBL7267435 | 0.88 | CACNA1D (0.59) | CACNA1CCACNA1DADORA3CACNA1BCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532110-B1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF ISOBUTYL METHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(2-NITROPHENYL)-3,5-PYRIDINE DICARBOXYLATE (NISOLDIPINE) | ERREGIERRE SPA (IT) | 2008-07-23 | — | — | EP | claimed |
| EP-0184841-B1 | 1,4-DIHYDROPYRIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1992-11-11 | — | — | EP | claimed |
| EP-0151989-B1 | MEANS FOR THE TREATMENT OF CARDIAC DISEASES | Ismail, Roshdy, Dr. (DE) | 1991-04-10 | — | — | EP | claimed |
| EP-0126094-A1 | NEW 1,4-DIHYDROPYRIDINE ESTERS AND PREPARATION METHODS THEREOF AND DRUGS CONTAINING SAID ESTERS. | CERMOL SA (CH) | 1984-11-28 | — | — | EP | claimed |
| WO-1984002132-A1 | NEW 1,4-DIHYDROPYRIDINE ESTERS AND PREPARATION METHODS THEREOF AND DRUGS CONTAINING SAID ESTERS | CERMOL SA (CH) | 1984-06-07 | — | — | WO | claimed |
| US-20250134908-A1 | THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITIS | CALOSYN PHARMA INC. | 2025-05-01 | — | — | US | disclosed |
| US-20240156756-A1 | TOPICAL WIPE CONTAINING NIFEDIPINE AND LIDOCAINE | STEEL THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| CN-111712241-B | Sigma-1 receptor agonist systolic blood pressure therapy | 阿纳韦克斯生命科学公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4312984-A1 | TOPICAL WIPE CONTAINING NIFEDIPINE AND LIDOCAINE | Steel Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-10940205-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2021-03-09 | — | — | US | disclosed |
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | THEMIS MEDICARE LIMITED (IN) | 2018-03-15 | — | — | US | disclosed |
| US-9827315-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | THEMIS MEDICARE LIMITED (IN) | 2017-11-28 | — | — | US | disclosed |
| US-4914159-A | Optically active (meth)acrylamides, a process for their preparation, and their use for racemate resolution | BAYER AKTIENGESELLSCHAFT (DE) | 1990-04-03 | — | — | US | disclosed |
| EP-0194906-B1 | HETEROCYCLIC DISSYMMETRIC 1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC-ACID ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTICAL USE | FOURNIER INNOVATION ET SYNERGIE (FR) | 1989-07-19 | — | — | EP | disclosed |
| US-4703119-A | Intermediates of optically active 1,4-dihydropyridines | BAYER AKTIENGESELLSCHAFT (DE) | 1987-10-27 | — | — | US | disclosed |
| EP-0194906-A2 | Heterocyclic dissymmetric 1,4-dihydropyridine-3,5-dicarboxylic-acid esters, process for their preparation and their therapeutical use | FOURNIER INNOVATION ET SYNERGIE (FR) | 1986-09-17 | — | — | EP | disclosed |
| EP-0126094-A1 | NEW 1,4-DIHYDROPYRIDINE ESTERS AND PREPARATION METHODS THEREOF AND DRUGS CONTAINING SAID ESTERS. | CERMOL SA (CH) | 1984-11-28 | — | — | EP | disclosed |
| WO-1984002132-A1 | NEW 1,4-DIHYDROPYRIDINE ESTERS AND PREPARATION METHODS THEREOF AND DRUGS CONTAINING SAID ESTERS | CERMOL SA (CH) | 1984-06-07 | — | — | WO | disclosed |
| US-4446325-A | VASODILATION, HYPOTENSIVE AGENTS | MARUKO SEIYAKU CO., LTD. (JP) | 1984-05-01 | — | — | US | disclosed |
| US-4021434-A | CEREBRAL VASODILATORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071390-A1 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES | DSG1, DEGS1, PLA2G2E | CACNA1C 3611/4885CACNA1D 3865/4885ADORA3 1574/4885 |
| US-10940205-B2 | Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives | DSG1, DEGS1, PLA2G2E | CACNA1C 3611/4885CACNA1D 3865/4885ADORA3 1574/4885 |
| US-20240156756-A1 | TOPICAL WIPE CONTAINING NIFEDIPINE AND LIDOCAINE | CACNA1C, CACNA1D, CACNB3 | CACNA1C 1/4885CACNA1D 2/4885ADORA3 1104/4885 |
| US-20250134908-A1 | THERAPEUTICS AND METHOD FOR TREATING OSTEOARTHRITIS | CA2, SLC16A1, ORAI1 | CACNA1C 30/4885CACNA1D 34/4885ADORA3 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.